Help | RSS Feed



Galapagos NV (NASD:GLPG) Seasonal Chart

Seasonal Chart Analysis

Analysis of the Galapagos NV (NASD:GLPG) seasonal charts above shows that a Buy Date of November 28 and a Sell Date of April 15 has resulted in a geometric average return of 19.51% above the benchmark rate of the S&P 500 Total Return Index over the past 11 years. This seasonal timeframe has shown positive results compared to the benchmark in 10 of those periods. This is an excellent rate of success, but the return underperforms the relative buy-and-hold performance of the stock over the past 11 years by an average of 4.17% per year.

The seasonal timeframe correlates Poorly with the period of seasonal strength for the Healthcare sector, which runs from April 25 to December 4. The seasonal chart for the broad sector is available via the following link: Healthcare Sector Seasonal Chart.

Galapagos NV is a clinical-stage biotechnology company, involved in the discovery and development of small-molecule medicines. The company’s product candidate portfolio includes Filgotinib, a JAK1 inhibitor to treat rheumatoid arthritis, Crohn’s disease, and ulcerative colitis; novel therapies in cystic fibrosis (a chronic disease that affects the lungs and digestive system); GLPG1690, a selective autotaxin inhibitor with potential application in idiopathic pulmonary disease; GLPG1972 to treat osteoarthritis; and MOR106 to treat atopic dermatitis.

To download GLPG seasonal chart data, please log in or Subscribe.

 

Stocks mentioned in this post:

    Search Seasonal Charts by Symbol, Company, or Term

   Symbols by Letter: A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z


Sponsored By...
Seasonal Advantage Portfolio by CastleMoore